Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| FOXO4-DRI | GHRP-2 | |
|---|---|---|
| Category | Peptides | Peptides |
| Standard Dose | Research indicates dosing remains experimental. Mouse studies used 5 mg/kg IV, three times weekly. | Research indicates 100-300 mcg administered 1-3 times daily via subcutaneous injection. |
| Timing | No established timing protocol. | On empty stomach, bedtime administration preferred. Wait 2+ hours after last meal. |
| Cycle Duration | Mouse studies used intermittent dosing (3x/week for several weeks). Human protocols not established. | 8-16 week cycles. |
| Evidence Level | animal_plus_anecdotal | moderate_human |
FOXO4-DRI is a D-retro-inverso peptide that selectively targets the FOXO4-p53 protein-protein interaction in senescent cells. In senescence, FOXO4 binds p53's disordered transactivation domain (TAD2) in the nucleus, preventing p53 from translocating to mitochondria where it would trigger apoptosis. FOXO4-DRI competitively disrupts this interaction, causing nuclear exclusion of p53 and its redirection to mitochondria, selectively inducing apoptosis in senescent cells while sparing healthy cells. The D-retro-inverso configuration provides protease resistance.
Research indicates dosing remains experimental. Mouse studies used 5 mg/kg IV, three times weekly.
No established timing protocol.
Mouse studies used intermittent dosing (3x/week for several weeks). Human protocols not established.
GHRP-2 (Growth Hormone Releasing Peptide-2) is a synthetic hexapeptide GHS-R1a agonist that is the most potent of the GHRP family for GH release. It stimulates pituitary GH secretion through the ghrelin receptor while also modulating hypothalamic GHRH and somatostatin pathways. GHRP-2 increases GH, cortisol, prolactin, and ACTH release, but with less appetite stimulation than GHRP-6. It also has demonstrated anxiolytic properties and sleep-promoting effects.
Research indicates 100-300 mcg administered 1-3 times daily via subcutaneous injection.
On empty stomach, bedtime administration preferred. Wait 2+ hours after last meal.
8-16 week cycles.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →